AN
ANAB.US AnaptysBio Inc
- Market cap
- USD 1.38B
- P/E
- 7.1x
- P/B
- 134.92x
- ROE
- 863.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ANAB.US undervalued?
Graham numberThe Graham number of AnaptysBio Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AnaptysBio Inc fundamental analysis
No fundamental analysis for AnaptysBio Inc yet.
AnaptysBio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AnaptysBio Inc
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agr…
Full company profileAnaptysBio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AnaptysBio Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 16.7M | 10.0M | 5.00M | 8.00M | 75.0M | 63.2M | 10.3M | 17.2M | 91.3M | 235M | 111M |
| Gross Profit | 1.27M | -19.4M | -51.2M | -91.3M | -5.03M | -35.3M | -78.5M | -115M | -72.6M | 232M | 78.7M |
| Operating Income | -3.03M | -28.8M | -66.7M | -107M | -23.9M | -56.8M | -115M | -164M | -115M | 47.9M | -779K |
| EBITDA | -3.57M | -28.1M | -59.9M | -95.9M | -19.4M | -55.7M | -105M | -155M | -92.7M | 69.2M | 9.07M |
| Net Income | -4.26M | -30.1M | -61.7M | -97.3M | -19.9M | -57.8M | -129M | -164M | -145M | -13.2M | 180M |
| EPS | -1.62 | -1.52 | -2.50 | -3.60 | -0.73 | -2.11 | -4.57 | -6.08 | -5.12 | -0.42 | 5.13 |
| Balance Sheet | |||||||||||
| Total Assets | 62.2M | 329M | 509M | 435M | 417M | 643M | 610M | 452M | 484M | 364M | 307M |
| Total Liabilities | 22.9M | 21.8M | 22.6M | 30.2M | 19.8M | 287M | 348M | 364M | 413M | 327M | 286M |
| Shareholders' Equity | 39.3M | 308M | 486M | 405M | 397M | 356M | 262M | 88.1M | 70.9M | 37.2M | 20.8M |
| Cash & Short-term Investments | 51.2M | 248M | 427M | 374M | 394M | 548M | 441M | 391M | 385M | 312M | 153M |
| Total Debt | 13.8M | 14.4M | 8.26M | 2.90M | 342K | 21.0M | 19.5M | 17.8M | 369M | 14.1M | 12.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.03M | -19.4M | -48.5M | -69.5M | -14.2M | -45.9M | -73.6M | -121M | -135M | 19.7M | -82.8M |
| Capital Expenditure | 50.0K | 290K | 1.06M | 805K | 569K | 1.37M | 358K | 807K | 358K | 87.0K | 45.3K |
| Free Cash Flow | -9.08M | -19.7M | -49.6M | -70.3M | -14.7M | -47.3M | -74.0M | -122M | -136M | 19.6M | -82.8M |
| Ratios | |||||||||||
| ROE | -10.8% | -9.8% | -12.7% | -24.0% | -5.0% | -16.2% | -49.1% | -185.7% | -204.9% | -35.6% | 863.7% |
| ROA | -6.8% | -9.1% | -12.1% | -22.4% | -4.8% | -9.0% | -21.1% | -36.2% | -30.0% | -3.6% | 58.6% |
| Net Profit Margin | -25.5% | -300.7% | -1,233.1% | -1,216.7% | -26.6% | -91.5% | -1,251.3% | -953.7% | -159.1% | -5.6% | 161.9% |
| Debt to Equity | 0.35x | 0.05x | 0.02x | 0.01x | 0.00x | 0.06x | 0.07x | 0.20x | 5.21x | 0.38x | 0.60x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AnaptysBio Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 11.7M | 0.44 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on Apr 20, 2026.
Who owns AnaptysBio Inc
- Insiders 6.10%
- Institutions 93.90%
- Public & others 0.00%
- Shares outstanding 29.7M
- Free float 20.4M
Top funds holding ANAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 687K | 2.30% | +2.68% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 648K | 2.17% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 508K | 1.70% | 0.00% | Oct 2026 |
| Nuveen Quant Small Cap Equity R6 | 219K | 0.73% | -17.02% | Aug 2026 |
| Fidelity Small Cap Index | 216K | 0.72% | +0.16% | Aug 2026 |
| iShares Biotechnology ETF | 215K | 0.72% | -0.19% | Oct 2026 |
| Federated Hermes Kaufmann Small Cap A | 210K | 0.70% | 0.00% | Sep 2026 |
| Invesco Biotechnology & Genome ETF | 199K | 0.66% | 0.00% | Oct 2026 |
| Victory Science & Technology | 188K | 0.63% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 188K | 0.63% | -0.38% | Oct 2026 |
| Fidelity Advisor Biotechnology I | 148K | 0.50% | 0.00% | Mar 2026 |
| First Trust Small Cap Gr AlphaDEX® ETF | 137K | 0.46% | +0.43% | Oct 2026 |
| Federated Hermes MDT Small Cap Core IS | 128K | 0.43% | +20.16% | Sep 2026 |
| Vanguard Russell 2000 ETF | 117K | 0.39% | +2.89% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 114K | 0.38% | +0.23% | Oct 2026 |
| Principal US Small Cap ETF | 98.3K | 0.33% | +0.05% | Oct 2026 |
| Fidelity Extended Market Index | 97.2K | 0.33% | -2.55% | Sep 2026 |
| Nomura Healthcare Fund Class I | 93.7K | 0.31% | 0.00% | Sep 2026 |
| Diamond Hill Small-Mid Cap I | 79.7K | 0.27% | 0.00% | Sep 2026 |
| Canada Life US Small-Mid Cap Growth F | 79.6K | 0.27% | 0.00% | Aug 2026 |
Top institutions holding ANAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 7.88M | 26.36% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.84M | 6.17% | +9.67% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 1.33M | 4.45% | 0.00% | Jun 2026 |
| State Street Corp | 1.29M | 4.30% | +29.60% | Jun 2026 |
| Vanguard Capital Management, LLC | 906K | 3.03% | +6.22% | Jun 2026 |
| Affinity Asset Advisors, LLC | 826K | 2.76% | -12.12% | Jun 2026 |
| Sanofi | 822K | 2.75% | 0.00% | Sep 2026 |
| Millennium Management LLC | 807K | 2.70% | +69.76% | Jun 2026 |
| Woodline Partners LP | 717K | 2.40% | +108.28% | Jun 2026 |
| Geode Capital Management, LLC | 638K | 2.13% | +22.61% | Jun 2026 |
| Palo Alto Investors, LLC | 603K | 2.02% | -5.43% | Jun 2026 |
| The Goldman Sachs Group Inc | 584K | 1.95% | +75.53% | Jun 2026 |
| First Light Asset Management, LLC | 582K | 1.95% | +2.93% | Jun 2026 |
| D. E. Shaw & Co LP | 540K | 1.81% | -6.84% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 528K | 1.77% | +1.54% | Jun 2026 |
| Apis Capital Advisors, LLC | 497K | 1.66% | +108.82% | Jun 2026 |
| Sofinnova Ventures | 494K | 1.65% | +98.80% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 489K | 1.63% | -0.70% | Jun 2026 |
| Nuveen, LLC | 421K | 1.41% | +33.09% | Jun 2026 |
| Bank of America Corp | 418K | 1.40% | -16.62% | Jun 2026 |
AnaptysBio Inc company profile
- Company name
- AnaptysBio Inc
- Ticker
- ANAB.US
- Exchange
- USA Stocks
- Listed since
- Jan 26, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 104
- Fiscal year end
- December
- Address
- 10770 Wateridge Circle, San Diego, CA, United States, 92121
- Phone
- 858 362 6295
- Website
- anaptysbio.com
About AnaptysBio Inc
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
AnaptysBio Inc management
4- Mr. Daniel R. FagaPresident, CEO & Director · born 1980
- Mr. Christopher M. MurphyChief Financial Officer · born 1984
- Ms. Beth MuellerSenior Vice President of Human Resources
- Mr. Benjamin StoneChief Business Officer · born 1991